Table 2.
Gene | Total (N=80) | Squamous cell carcinoma (SCC) (N=40) |
Adenocarcinoma (AC) (N=40) |
P-value |
---|---|---|---|---|
Any PIK3CA mutation1 | 25 (31.3) | 15 (37.5) | 10 (25.0) | 0.33 |
E542K | 10 (12.5) | 6 (15.0) | 4 (10.0) | |
E545K | 16 (20.0) | 10 (25.0) | 6 (15.0) | |
E453K | 1 (1.3) | 0 (0.0) | 1 (2.5) | |
3R88Q | 1 (1.3) | 0 (0.0) | 1 (2.5) | |
Any KRAS mutation | 7 (8.8) | 0 (0.0) | 7 (17.5) | 0.01 |
G12A | 1 (1.3) | 0 (0.0) | 1 (2.5) | |
G12D | 3 (3.8) | 0 (0.0) | 3 (7.5) | |
G12V | 2 (2.5) | 0 (0.0) | 2 (5.0) | |
G13D | 1 (1.3) | 0 (0.0) | 1 (2.5) | |
EGFR mutation2 | 3 (3.8) | 3 (7.5) | 0 (0.0) | 0.24 |
Any PTEN loss3 | 4 (7.8) | 3 (13.0) | 1 (3.6) | 0.32 |
3/80 (3.8%) of samples had combined PIK3CA mutations (e.g., E542K and E545K).
Two additional squamous cell carcinomas had EGFR S703F detected with hME chemistry or Illumina sequencing.
51 samples were available for immunohistochemistry to detect PTEN loss (28 AC and 23 SCC).